The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors.
C. D. Weekes
Honoraria - Genentech
P. LoRusso
Consultant or Advisory Role - Genentech
V. Ramakrishnan
Employment or Leadership Position - Roche
Stock Ownership - Roche
L. M. Shih
Employment or Leadership Position - Roche
Stock Ownership - Roche
W. C. Darbonne
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
P. Hegde
Employment or Leadership Position - Roche
Stock Ownership - Roche
Y. Xin
Employment or Leadership Position - Roche
Stock Ownership - Roche
R. Yu
Employment or Leadership Position - Roche
Stock Ownership - Roche
H. Xiang
Employment or Leadership Position - Roche
Stock Ownership - Roche
R. K. Brachmann
Employment or Leadership Position - Roche
Stock Ownership - Roche
A. Patnaik
Honoraria - Roche